Ownership and insider activity for IN8bio, Inc. (INAB): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
IN8bio, Inc. is a biotechnology firm currently in the clinical trial phase, dedicated to identifying, advancing, and bringing to market gamma-delta T cell-based treatments specifically for various forms of cancer. The company's primary therapeutic asset, INB-200, is an autologous (patient-derived) gamma-delta T cell product that has been genetically engineered and is presently undergoing a Phase I clinical study for glioblastoma and other solid tumor malignancies.
Price
| Price | $1.01 |
| Market Cap | $10M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-05-27 | FAIRBAIRN EMILY | G-Gift | 724,637 | |
| 2026-05-09 | Ho William Tai-Wei | A-Award | 154,500 | $244K |
| 2026-05-09 | Greenwood Luba | A-Award | 22,000 | $35K |
| 2026-05-09 | Lamb Lawrence | A-Award | 54,000 | $85K |
| 2026-05-09 | FAIRBAIRN EMILY | A-Award | 22,000 | $35K |
| 2026-05-09 | McCall Patrick | A-Award | 56,250 | $89K |
| 2026-05-09 | Rochlin Kate | A-Award | 60,000 | $95K |
| 2026-05-09 | Epperly Corinne | A-Award | 22,000 | $35K |
| 2026-05-09 | Brandt Peter C. | A-Award | 22,000 | $35K |
| 2026-05-09 | Graff Jeremy R. | A-Award | 22,000 | $35K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $5.0M | $610000 | $18.0M | $37.0M | $18.2M | $21.3M | $11.1M | $27.1M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | $30000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Inventory | $15000 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $5.1M | $763000 | $18.1M | $39.0M | $22.2M | $24.6M | $12.6M | $27.9M |
| Property, Plant & Equipment | $795000 | $274000 | $186000 | $2.8M | $10.3M | $8.6M | $7.8M | $4.0M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | $126000 | 0 | 0 | 0 |
| Total Assets | $5.9M | $1.1M | $20.9M | $42.2M | $33.0M | $33.7M | $20.9M | $32.3M |
| Accounts Payable | $419000 | $560000 | $620000 | $395000 | $2.1M | $924000 | $389000 | $309000 |
| Short-term Debt | 0 | 0 | $174000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $419000 | $647000 | $2.6M | $2.3M | $5.8M | $5.4M | $3.1M | $3.2M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.6M |
| Total Liabilities | $1.2M | $1.5M | $2.6M | $4.0M | $10.3M | $8.8M | $6.5M | $4.7M |
| Retained Earnings | -$4.3M | -$9.5M | -$18.0M | -$32.7M | -$61.2M | -$91.2M | -$121.7M | -$141.1M |
| Total Equity | $4.6M | -$346000 | $18.3M | $38.2M | $22.7M | $24.9M | $14.5M | $27.6M |
| Total Debt | 0 | 0 | $174000 | $2.4M | $5.9M | $4.9M | $5.0M | $2.8M |
| Net Debt | -$5.0M | -$610000 | -$17.8M | -$34.6M | -$12.3M | -$16.4M | -$6.1M | -$24.3M |
| Working Capital | $4.7M | $116000 | $15.6M | $36.7M | $16.4M | $19.2M | $9.5M | $24.7M |
Related companies: ACXP · APRE · APVO · BCDA · GLTO · HCWB · KPRX
Explore sector: Healthcare · Biotechnology
More sections of INAB: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks